Medical
Health
Therapy

Portola Pharmaceuticals

$31.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.66 (-4.94%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PTLA and other stocks, options, ETFs, and crypto commission-free!

About

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. Read More The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Employees
324
Headquarters
South San Francisco, California
Founded
2003
Market Cap
2.13B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.47M
High Today
$33.49
Low Today
$31.91
Open Price
$33.37
Volume
430.89K
52 Week High
$45.60
52 Week Low
$14.81

Collections

Medical
Health
Therapy
Technology
Pharmaceutical
2013 IPO

News

The Motley FoolMar 1

Why Portola Pharmaceuticals Skyrocketed 15.3% Today

What happened After it reported fourth-quarter results and solidified its cash position without issuing more shares, Portola Pharmaceuticals (NASDAQ:PTLA) shares had gained 15.3% at noon EST on Friday. So what Portola Pharmaceuticals has struggled in its bid to go from promising clinical-stage upstart to commercial-stage darling. Despite Food and Drug Administration (FDA) approval for two distinct therapies, lackluster sales have dampened investors' enthusiasm. In its fourth-quarter earnings report, the...

1,156
Seeking AlphaMar 1

Portola Pharmaceuticals beats by $0.07, beats on revenue

Portola Pharmaceuticals (NASDAQ:PTLA): Q4 Non-GAAP EPS of -$1.04 beats by $0.07; GAAP EPS of -$1.34 misses by $0.23. Revenue of $15.3M (+56.1% Y/Y) beats by $4.35M . Shares +4.36% PM. Press Release...

286
Seeking AlphaFeb 28

Portola Pharmaceuticals Q4 Earnings Preview

Portola Pharmaceuticals (NASDAQ:PTLA) is scheduled to announce Q4 earnings results on Friday, March 1st, before market open. The consensus EPS Estimate is -$1.11 (+21.3% Y/Y) and the consensus Revenue Estimate is $10.95M (+11.7% Y/Y). Over the last 2 years, PTLA has beaten EPS estimates 63% of the time and has beaten revenue estimates 50% of the time....

85

Earnings

-$1.62
-$1.41
-$1.19
-$0.98
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.